Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Claudia Bodenstein"'
Autor:
Harvey R. Herschman, Wolfgang Weber, Yann Seimbille, Claudia Bodenstein, Rebecca A. Dumont, Steven M. Dubinett, Helen Su, Johannes Czernin, Michael E. Phelps
Publikováno v:
Clinical Cancer Research. 12:5659-5667
Purpose: The mechanisms underlying the sensitivity of non–small cell lung cancer to epidermal growth factor receptor (EGFR) kinase inhibitors are complex, and there are no established markers to accurately predict treatment outcome in individual pa
Autor:
Roland Haubner, Reingard Senekowitsch-Schmidtke, M. Schwaiger, Hans-Jürgen Wester, Claudia Bodenstein, Bertrand Kuhnast, Wolfgang A. Weber
Publikováno v:
Nuclear Medicine and Biology. 31:337-344
Matrix metalloproteinases (MMPs) are a family of proteinases that play an important role in cancer as well as in numerous diseases. In this article, we describe the labeling of a phage display selected cyclic decapeptide containing the HWGF (histidin
Autor:
Bryan E. Essien, Heinz Bönisch, Roland Haubner, Martina Anton, Bernd Gansbacher, Claudia Bodenstein, Wolfgang A. Weber, Markus Schwaiger, Bettina Wagner
Publikováno v:
The Journal of Gene Medicine. 6:119-126
BACKGROUND: The norepinephrine transporter (NET) is a high-affinity transporter for catecholamines. Its expression is almost exclusively restricted to the sympathetic nervous system. In this study we evaluated whether the NET can be used as a reporte
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 46:539-553
Matrix metalloproteinases (MMPs) are a family of proteinases that play an important role in cancer. Non invasive imaging of MMPs would allow the evaluation of MMP activity in cancer and the assessment of the response of MMP inhibitor based therapies.
Autor:
W. Linke, Wolfgang A. Weber, Roland Haubner, HJ Wester, Claudia Bodenstein, Horst Kessler, M. Schwaiger
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 44:S157-S159
Autor:
Claudia Bodenstein, Michael E. Phelps, Kevin J. Kim, Yann Seimbille, Wolfgang A. Weber, Johannes Czernin, Helen Su, Steven M. Dubinett, Barbara J. Fueger, Gregory Z. Ferl, Yu-Tien Hsu
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No 6 (2008) pp. 1089-1099
PURPOSE: Gefitinib, an inhibitor of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK), has shown potent effects in a subset of patients carrying specific EGFR-TK mutations in advanced non-small-cell lung cancer. In this study, we asked w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::383edb0e75e71b0c1d1aa8e2fe9eb305
https://archive-ouverte.unige.ch/unige:19093
https://archive-ouverte.unige.ch/unige:19093
Publikováno v:
Journal of Investigative Medicine. 54:S139.2-S139
Objectives Small molecule inhibitors of the epidermal growth factor receptor (EGFR) kinase have recently been introduced for treatment of non-small cell lung cancer (NSCLC). However, these new drugs are only effective in approximately 10% of patients